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Abstract
Background: Hepatic resection is still associated with significant morbidity. Although the period of parenchymal
transection presents a crucial step during the operation, uncertainty persists regarding the optimal technique of
transection. It was the aim of the present randomized controlled trial to evaluate the efficacy and safety of hepatic
resection using the technique of stapler hepatectomy compared to the simple clamp-crushing technique.
Methods/Design: The CRUNSH Trial is a prospective randomized controlled single-center trial with a two-group
parallel design. Patients scheduled for elective hepatic resection without extrahepatic resection at the Department
of General-, Visceral- and Transplantation Surgery, University of Heidelberg are enrolled into the trial and
randomized intraoperatively to hepatic resection by the clamp-crushing technique and stapler hepatectomy,
respectively. The primary endpoint is total intraoperative blood loss. A set of general and surgical variables are
documented as secondary endpoints. Patients and outcome-assessors are blinded for the treatment intervention.
Discussion: The CRUNSH Trial is the first randomized controlled trial to evaluate efficacy and safety of stapler
hepatectomy compared to the clamp-crushing technique for parenchymal transection during elective hepatic resection.
Trial Registration: ClinicalTrials.gov: NCT01049607
Background
Hepatic resection forms the cornerstone of therapy for a
variety of benign and malignant diseases of the liver [1].
While advances in patient selection, surgical technique,
perioperative management and imaging tools reduced
mortality substantially, morbidity of patients undergoing
hepatic resection remains as high as 30-60% even at
high-volume centers [2-7]. Due to the risk of intraopera-
tive hemorrhage as well as postoperative morbidity (e.g.
bile leakage, posthepatectomy hemorrhage), the period
of actual transection of the liver parenchyma represents
a crucial step during hepatic resection. Various studies
could indeed demonstrate intraoperative hemorrhage as
predictor of poor perioperative outcome in patients
undergoing hepatic resection [1,8]. Although various
devices have been developed to facilitate parenchymal
transection with the ultimate aim to reduce intraopera-
tive blood loss [9], a recent systematic review and meta-
analysis failed to show a benefit of these tools compared
to the simple clamp-crushing technique [10]. However,
to the present there is no randomized controlled trial
(RCT) evaluating the technique of stapler hepatectomy.
Based on the well-established role of stapling devices in
various surgical fields and their common use for division
of hepatic veins and portal branches [11-13], vascular
staplers may facilitate rapid division of the liver par-
enchyma with immediate sealing of vascular and biliary
structures. In theory, these features enable hepatic resec-
tion to be being carried out with less intraoperative
blood loss as well as lower operation time.
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Several recent systematic review articles including a
Cochrane review on transection techniques showed that
there is a lack of high-level evidence, i.e. randomized
controlled trials, on the use of stapling devices for par-
enchymal transection in elective hepatic resection
[9,10,14,15]. While there are several articles on the tech-
nique of stapler hepatectomy as well as retrospective
non-controlled studies [16-18], there is currently no RCT
evaluating efficacy and safety of stapler hepatectomy
compared to standard technique of parenchymal transec-
tion. The largest single-center experience on stapler
hepatectomy has been reported from the Department of
Surgery, University of Heidelberg. This analysis com-
prised 300 patients who underwent hepatic resection
using the technique of stapler hepatectomy for transec-
tion of the parenchyma [19]. Even though this report and
others suggests stapler hepatectomy to be rapidly feasible
as well as effective and safe in controlling intraoperative
blood loss [14,20], it’s retrospective, non-randomized
study design does not justify general recommendations.
Aim of this trial
There is clinical uncertainty and ongoing discussion
among liver surgeons regarding the optimal method of
parenchymal transection in patients undergoing elective
hepatic resection. While the clamp-crushing technique
still represents the reference technique for routine liver
resections [10], transection of liver parenchyma using
vascular staplers may offer a new and safe technique
potentially reducing intraoperative blood loss, operation
time as well as peri-operative morbidity. As morbidity of
patients undergoing hepatic resection remains high,
approaches to reduce peri-operative complications are
urgently required. Due to the lack of evidence it has to
be evaluated, if the technique of stapler hepatectomy
decreases intraoperative blood loss as a known predictor
of peri-operative morbidity compared to the clamp-
crushing technique. In case of comparable or more
favorable secondary outcomes such as peri-operative
mortality, transection time and need for re-interven-
tions, this advantages would favor stapler hepatectomy
as a routine technique for elective liver resections. As
RCTs are generally considered to generate the most
valid scientific evidence on a treatment’s effects, the effi-
cacy and safety of stapler hepatectomy needs to be eval-
uated in a randomized fashion.
Methods/Design
Trial population and patient recruitment
Patients scheduled for elective hepatic resection at the
Department of General-, Visceral- and Transplantation
Surgery, University of Heidelberg will be screened for
enrollment into the trial. Patients meeting the eligibility
criteria will be enrolled into the study. Informed consent
is obtained at least on the day before surgery.
Subject Inclusion Criteria
Subjects matching the following criteria are eligible for
inclusion into the clinical trial:
￿ Patients scheduled for elective hepatic resection
￿ Stapler hepatectomy and clamp-crushing feasible
based on preoperative imaging
￿ Age equal or greater than 18 years
￿ Informed consent
Subject Exclusion Criteria
Subjects matching any of the following criteria must not
be included into the clinical trial:
￿ Concomitant extraheptic resection planned
￿ Participation in concurrent intervention trials
￿ Expected lack of compliance
￿ Impaired mental state or language problems
Study objectives and endpoints
The primary objective of this trial is to show that intrao-
perative blood loss during elective hepatic resection can
be reduced by stapler hepatectomy as compared to the
clamp-crushing technique.
The primary efficacy endpoint of the CRUNSH Trial
is total intraoperative blood loss [ml], which is defined
as blood loss from skin incision until closure of the
skin. Intraoperative blood loss is measured according to
the blood collected in the suction containers. Spilling
water and ascites is subtracted. Furthermore, swabs are
squeezed and their content will also be sucked and
added to the fluid collected in the suction containers.
To obtain a more precise estimate for the individual
patient patient’s individual transection area will be con-
sidered as a continuous covariate multivariate analysis.
The transection area will be assessed using an imprint
of the resected specimen on a paper sheet with a known
density of 80 mg/m
2.
To further evaluate efficacy and safety of stapler hepa-
tectomy compared to the clamp-crushing technique, a
set of general as well as surgical variables are documen-
ted as secondary endpoints [21]. The secondary end-
points of the trial are summarized together with their
definition in Table 1.
Standardisation of treatments
Patients’ intra- and perioperative care will be standar-
dized and kept identical except for the technique of
hepatic transection.
Patients receive combined neuraxial and general
anaesthesia. However, general anesthesia alone may be
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the executing anesthesiologist and lack of patient
consent.
Following laparotomy via an extended right subcostal
incision, a bilateral subcostal incision (with or without
vertical midline extension or a reversed L-shaped inci-
sion from xiphoid to the tip of the twelfth right rib the
abdomen is initially explored for extrahepatic disease.
Intraoperative ultrasound of the liver is carried out
regularly to exclude previously undetected lesions.
Transection of the hepatic parenchyma is carried out
under low central venous pressure (< 5 cmH2O). Cen-
tral venous pressure (CVP) is lowered via fluid restric-
tion and clamping of the inferior vena cava (IVC) [22].
If these prove insufficient to lower CVP to a level < 5
cmH2O, the Trendelenburg position and administra-
tion of nitrocompounds may be used in addition.
Resections are carried out without use of hepatic
inflow control (i.e. portal triad clamping). However,
inflow control may be used by the surgeon, if consid-
ered necessary and will be documented as a secondary
endpoint. Transfusion of PRBC within the CRUNSH
Trial is standardized accoriding to the standards of
care at the Department of General-, Visceral- and
Transplantation and the Department of Anesthesiol-
ogy, University of Heidelberg (Table 2).
Argon beam coagulation is applied to stop minor ooz-
ing once resection is completed and sealants may be
used, if deemed necessary by the executing surgeon.
After hemostasis is considered secure, easy-flow drains
are placed in the subphrenic and subhepatic space and
the abdomen is closed in a standardized manner.
Trial interventions
Group A: Clamp-crushing technique
The transectional line is marked and the liver capsule is
cauterized. The liver parenchyma is then crushed step-
wise using a regular Pèan clamp. Vessels of less than 2
mm in diameter are coagulated with the irrigated bipo-
lar forceps. The remaining vessels are clipped or ligated.
The hepatic veins and the portal triad are divided using
sutures or the Autosuture Endo Gia™ Universal Stapler
Table 1 Secondary endpoints of the CRUNSH Trial
Secondary endpoint Definition and assessment of outcomes
Blood loss during liver transection
[mL]
Blood loss from beginning of parenchymal transection until minor oozing is stopped. To assess blood loss
during liver transection the suction device will be connected to a new suction container for the period of actual
hepatic transection.
Blood transfusion: Administration of blood transfusions is documented for the intraoperative and postoperative period until 48
hours postoperatively. Documentation includes number of patients who received blood transfusions as well as
amount of transfused packed red blood cells (PRBC) [units].
Operation time [min]: Time from skin incision to placement of last skin staple/suture.
Liver transection time [min]: Time from beginning to end of liver transection.
Duration of postoperative hospital
stay [days]:
Time from day of operation to day of discharge.
Duration of ICU stay [days]: Time on the Intensive Care Unit (ICU). Patients’ stay in the recovery room and Intermediate Care (IMC) unit
exceeding 24 hours is considered as ICU stay.
Morbidity: The following predefined complications are documented within the CRUNSH Trial:
Posthepatectomy hemorrhage [23]: Drop of hemoglobin level > 3 g/dl after the end of surgery compared to
postoperative baseline level and/or any postoperative transfusion of PRBCs for a falling hemoglobin and/or the
need for invasive re-intervention (e.g. embolization or re-laparotomy).
Postoperative biliary leakage [24]: Presence of bile fluid (bilirubin level more than three times the serum level) in
the abdominal cavity or drains on or after postoperative day or the need for reintervention (i.e. interventional
drainage and/or relaparotomy due to bile fluid collections or biliary peritonitis).
Further biliary complications: Biliary complications such as postoperative biliary stricture detected via ERCP and/
or MRCP
Intraabdominal fluid collection/abscess: Intraabdominal fluid collection detected on any imaging modality (e.g.
ultrasound, CT scan) associated with abdominal discomfort/pain and/or elevation of infectious parameters.
Posthepatectomy liver failure [25]: Increased INR or need of coagulation products (FFP, coagulation factors) to
normalize the INR and increased serum bilirubin on or after postoperative day five.
Pneumonia: Pulmonary infection with evidence of increased infection parameters (CRP > 2 mg/dl and/or
leukocytes > 10 0000/ml) which are unlikely to be caused by a different pathologic process and evidence of
pulmonary infiltrates on chest x-ray, requiring antibiotic therapy.
In-hospital mortality: Death due to any reason within the patient’s initial hospital stay.
Liver biochemical tests: Serum levels of Alanine-Aminotransferase (ALT), Aspartate-Aminotransferase (AST), Gamma-glutamyl transferase
(GGT), Quick’s time/INR, Total Bilirubin, Albumin on postoperative day 1, 3 and 5.
Need for portal triad clamping: Need for clamping of the hepatic pedicle to control intraoperative hemorrhage.
Resection margins The proportion of patients with malignant tumors who have a positive resection margin will be documented.
Need for invasive re-interventions: Invasive re-interventions such as placement of interventional drains, ERCP with stent placement and re-
laparotomy within 30 days after the index operation or during patients’ initial hospital stay.
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units with 2.5 mm staples (Covidien).
Group B: Stapler hepatectomy
The transectional line is marked and the liver capsule is
cauterized. For subsequent transection of the hepatic
parenchyma, the liver tissue is fractured with a vascular
clamp in a stepwise fashion and subsequently divided
using the Autosuture Endo Gia™ Universal Stapler and
Endo Gia™ Universal Straight 60 mm loading units
with 2.5 mm staples (Covidien). The hepatic veins and
the portal triad are divided using the Autosuture Endo
Gia™ Universal Stapler and Endo Gia™ Universal
Angulating 45 mm loading units with 2.5 mm staples
(Covidien).
Trial implementation
Patients scheduled for elective hepatic resection are
screened consecutively for inclusion into the trial. All
patients screened for the CRUNSH Trial are documen-
ted in the screening log. Patients meeting the inclusion
criteria are enrolled in the trial. Informed consent has
to be obtained at least on the day prior to surgery.
Study visits within the CRUNSH Trial are displayed in
Table 3.
Methods against Bias
Randomization
Patients are screened consecutively and all eligible
patients are included into the trial. In order to achieve
comparable groups and ensure allocation concealment
patients are randomly allocated to the study groups. A
block randomisation list is generated by the Institute for
Medical Biometrics and Informatics (IMBI) applying
SAS (SAS™ Version 9.1., SAS Institute Inc., Cary,
USA). Randomization is carried out intraoperatively in
case resectability is given. Randomization is carried out
using opaque and sealed envelopes that are consecu-
tively numbered. Block randomization will be performed
for each center to achieve equal group sizes per center.
The details of randomization will be kept in safe and
confidential. Subjects withdrawn from the trial retain
their identification codes (e.g. randomization number).
New subjects receive a new identification code.
Blinding
Patients are blinded for the study intervention. Blinding
of the surgeon and people in the operating room is not
feasible. Therefore a third party blinded to patients’ allo-
cated treatment group assesses postoperative outcomes.
Standardization of care
To assure comparable treatment of patients, all surgeons
who participate in this trial, will be instructed on both
study interventions. Intra-and perioperative care is stan-
dardized. In particular, central venous pressure (CVP)
will be lowered to < 5 mmHg for the period of parench-
ymal transection and resections in both study arms will
be performed without routine use of the vascular con-
trol. Furthermore, the area of resection will be included
in the multivariate analysis as a continuous covariate.
Sample size
The sample size is based on the primary outcome para-
meter and the primary analysis. Internal observations
(Department of Surgery, University of Heidelberg)
showed a mean intraoperative blood loss of 700 ml for
patients undergoing stapler hepatectomy with a sample
standard deviation of about 550 ml [19]. To detect a
clinically relevant absolute difference reduction in
intraabdominal blood loss of 280 ml with significance a
= 5% and a power of (1-b) = 80% n = 122 patients have
to be randomized in the study (n = 61 patients per
group) using two-sided t-test. Considering an estimated
intraoperative drop-out rate of about 10% (e.g. unex-
pected death prior to beginning of transection, protocol
violations) eight additional patients will be randomized
and the total sample size accounts for n = 130 patients
(n = 65 patients per group).
Table 2 Transfusion triggers within the CRUNSH Trial
Risk profile Minimum hemoglobin (conversion factor 0.621)
< 40 years
no additional risk factors
no organ function impairment
< 5.5 g/dl or 3.4 mmol/l
≥ 40 years
no additional risk factors
no organ function impairment
< 6 g/dl or 3.7 mmol/l
organ function impairment < 7 g/dl or 4.3 mmol/l
coronary artery disease with no ischemia
carotid artery stenosis with no ischemia
history of transient ischemic attack
< 8 g/dl or 5.0 mmol/l
coronary artery disease with ischemia e.g. troponin elevation
carotid artery stenosis with ischemia
history of stroke
< 10 g/dl or 6.2 mmol/l
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Statistical methods are used to assess the quality of data,
homogeneity of treatment groups, endpoints and safety
of the two intervention groups. The confirmatory analy-
sis is performed on the basis of an intention-to-treat
(ITT) population and with respect to ITT principles.
Categorical data are summarized by means of absolute
and relative frequencies (count and percent). Continu-
ous data are presented by means of the following sum-
mary statistics: the number of observations, median,
minimum, median and maximum. Wherever appropri-
ate, data are visualized by box-whisker plots or histo-
grams. The primary efficacy endpoint is amount of total
intraoperative blood loss. The underlying two-sided
null-hypothesis is that both study interventions lead to
similar intraoperative blood loss:
H0 : µ1 − µ2=0
The alternative is that one intervention performs bet-
ter than the other:
H1 : µ1 − µ2  = 0
A confirmatory intention-to-treat analysis (2-sided
test), including all patients as randomized, is performed
on the amount of intraoperative blood loss between the
two groups. Analysis of covariance (ANCOVA) is used
to detect possible treatment differences with intraopera-
tive blood loss as dependent variable, area of resection
and CVP during transection as continuous covariates
and type of intervention as factor. The sample size cal-
culation is based on a two-sided t-test, and it can be
assumed that evaluation with analysis of covariance has
the same or even higher power.
Secondary endpoints will be analyzed in an explora-
tory way, using appropriate statistical methods based on
the underlying distribution of the data. All analysis will
employ SASa Version 9.1.
Data management and quality assurance
The investigator or a designated representative enters all
protocol-required information in the case report form
(CRF). The CRF should be completed as soon as possi-
ble after the information is collected, preferably on the
same day when a trial subject is seen for an examina-
tion, treatment, or any other trial procedure. The reason
for missing data should be provided. The investigator is
responsible for ensuring that all sections of the CRF are
completed correctly and that entries can be verified in
accordance with the source data.
The completed CRF must be reviewed and signed by
the investigator named in the trial protocol or by a
designated sub-investigator. The principle investigator
will retain originals of all CRF at the end of the trial
Monitoring within the CRUNSH Trial is carried out
by an independent investigator at the Department of
Surgery, University of Heidelberg, who is not involved
in the trial and in completing the CRFs. The basic data
of all participating patients are completely checked, i.e.
existing patient, patient number, initials, the availability
of signed informed consent. For a proportion of 10% of
the study participants (randomly selected) a complete
check of all data in the CRF (i.e. a 100% clinical source
data verification; SDV) is carried out. The extent of
further SDV is dependent on the quality of the data and
occurrence of protocol violations.
Ethical and legal considerations
The study is conducted in agreement with either the
Declaration of Helsinki (Tokyo, Venice, Hong Kong,
Somerset West and Edinburgh amendments) or the laws
and regulations of the country, whichever provides the
greatest protection of the patient. The protocol has been
written, and the study will be conducted according to
the ICH Harmonized Tripartite Guideline for Good
Clinical Practice (ref: http://www.ich.org/fileadmin/
Table 3 Flow chart of the CRUNSH Trial
Screening Intervention Follow Up
Visit 1
(up to 5 days before surgery)
Visit 2
(day of surgery)
Visit 3
(POD 1)
Visit 4
(POD 3)
Visit 5
(POD 7 or day of discharge)
Eligibility criteria Informed consent ·
Medical history ·
Demographics ·
Physical examination ·
Laboratory tests ·· · ·
Randomization ·
Trial intervention ·
Intraoperative parameters ·
Postoperative parameters ·· ·
POD, Postoperative day
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E6_R1/Step4/E6_R1__Guideline.pdf).
The trial protocol is approved by the local indepen-
dent ethics committee of the University of Heidelberg
approved the trial protocol, the patient information and
informed consent sheet.
The CRUNSH Trial is registered at the ClinicalTrials.
gov protocol registration system (NCT01049607).
All patients will be informed of the aims of the study,
the possible adverse events, the procedures and possible
hazards to which he/she will be exposed to, and the
mechanism of treatment allocation. They will be
informed as to the strict confidentiality of their patient
data, but that their medical records may be reviewed for
trial purposes by authorized individuals other than their
treating physician. The signed consent document is kept
by the investigator. A copy of the signed consent docu-
ment is handed out to the subject or the subject’s legally
authorized representative.
It will be emphasized that the participation is volun-
tary and that the patient is allowed to refuse further
participation in the study whenever he/she wants. This
will not influence the patient’s subsequent care. Docu-
mented informed consent must be obtained for all
patients included in the study before they are registered
o rr a n d o m i z e di nt h es t u d y .T h i sm u s tb ed o n ei n
accordance with the national and local regulatory
requirements.
It is the responsibility of the investigator to maintain
patient’s confidentiality. During the trial, patients will be
identified solely by means of their initials, age and indi-
vidual identification code (screening number, randomi-
zation number). Trial findings will be stored in
accordance with local data protection law/ICH GCP
Guidelines and will be handled in strictest confidence.
For protection of these data, organizational procedures
are implemented to prevent distribution of data to
unauthorized people.
The investigator will maintain a personal subject iden-
tification list (screening numbers with the corresponding
subject names) to enable records to be identified.
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